<DOC>
	<DOCNO>NCT02308072</DOCNO>
	<brief_summary>The phase I trial aim determine recommend phase II dose ( RP2D ) schedule olaparib combination standard cisplatin-based chemoradiotherapy , patient high-risk locally advanced squamous cell carcinoma head neck ( HNSCC ) , assess safety tolerability treatment combination .</brief_summary>
	<brief_title>Phase I Study Olaparib Combined With Cisplatin-based Chemoradiotherapy Treat Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>ORCA-2 phase I trial patient locally advance , without metastatic nodal disease . Patients receive olaparib ( PARP inhibitor ) combination standard cisplatin-based chemotherapy intensity modulate radiotherapy ( IMRT ) . Olaparib , cisplatin radiotherapy give combination every week maximum 7 week . Prior start combination treatment , olaparib start 7 day first week combination treatment . Olaparib give twice daily day 1-3 week treatment ( either alone week 0 combination chemotherapy radiotherapy week 1-7 ) . Cisplatin start day 1 week , give week radiotherapy treatment total 7 week . Radiotherapy deliver day 1-5 week use IMRT , total 7 week . The phase I trial aim determine recommend phase II dose olaparib ( 50mg , 100mg , 150mg 200mg bd ) - dose olaparib patient receive depend dose investigation time patient registration . Dose escalation guide two-dimensional dose escalation design call Product Independent Beta Probabilities escalation ( PIPE ) . It recommend choice dose/duration combination cohort olaparib subsequent patient estimate contour divide dose/duration combination cohort target toxicity rate ( equal 33 % ) . The recommended phase II cohort ( ) experiment trial also close ( ) estimate contour calculate use trial data .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histologically confirm highrisk locally advanced HNSCC , patient would normally offer cisplatinbased radical chemoradiotherapy 2 . Estimated life expectancy least 16 week 3. WHO performance status 0 1 4 . Aged ≥18 year 5 . Adequate bone marrow function : absolute neutrophil grade 0 1 , platelet grade 0 1 , haemoglobin grade 0 1 6 . Adequate renal function : Creatinine grade 0 1 , Calculated GFR ≥60 mL/min ( calculate value &lt; 60 mL/min isotope GFR assessment perform estimation 24h urine collection ) 7 . Adequate liver function : Serum bilirubin grade 0 1 , AST ALT grade 0 1 8 . Patients must able swallow olaparib tablet 9 . Willing use contraception duration trial treatment six month completion treatment 10 . Able give inform consent 11 . Patients willing able comply protocol duration study 1 . Head &amp; neck cancer follow type : Nasopharyngeal paranasal sinus tumour , Oral squamous cell carcinoma ( tumours oral cavity ) , Low risk Human Papilloma Virus positive oropharyngeal tumour ( tonsillar tongue base tumour ) 2 . Confirmed distant metastatic disease 3 . Previous chemotherapy radiotherapy treatment HNSCC tumour 4 . Previous therapy PARP inhibitor 5 . Chemotherapy , immunotherapy radiotherapy within 28 day prior registration 6 . Prior history malignancy , except basal cell squamous cell carcinoma skin , carcinoma situ cervix , breast prostate . Patient must free malignancy period 3 year prior first dose trial drug 7 . Women pregnant lactate 8 . Preexisting gastrointestinal disorder may interfere delivery absorption olaparib 9 . Grade 3 4 peripheral neuropathy If consider significant treat clinician low grade neuropathy may consider exclusion criterion 10 . Significant hearing difficulty tinnitus ( deaf patient include ) Whilst exclude , patient mildly impair hear tinnitus must make aware potential ototoxicity may choose include . If include , recommend audiogram carry baseline . 11 . Any serious and/or unstable preexist medical , psychiatric condition , treat clinician 's judgment , could interfere patient safety obtain informed consent 12 . Known hepatitis B C infection ( test Hepatitis HIV trial mandatory ) 13 . Immunocompromised patient ( e.g . know HIV positive status ) 14 . Active uncontrolled infection 15 . The current use drug know inhibit induce CYP3A4 16 . Resting ECG QTc &gt; 470msec 2 time point within 24 hour period family history long QT syndrome . 17 . Patients myelodysplastic syndrome/acute myeloid leukaemia . 18 . Patients know hypersensitivity olaparib excipients product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Locally Advanced</keyword>
	<keyword>Olaparib</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>IMRT</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>PARP</keyword>
	<keyword>HNSCC</keyword>
</DOC>